Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dapirolizumab pegol by UCB for Systemic Lupus Erythematosus: Likelihood of Approval
Dapirolizumab pegol is under clinical development by UCB and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...